Login to Your Account

Osiris Regains Prochymal via Public Brushoff from Sanofi

By Catherine Shaffer
Staff Writer

Monday, February 13, 2012
The breakup of a $1.38 billion stem cell partnership between Genzyme Corp. and Osiris Therapeutics Inc., dating to 2008, was heralded by an offhand mention in a Sanofi SA post-Genzyme-acquisition pipeline update, sending the biotech's shares down 15 percent Thursday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription